These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31573759)

  • 1. Characterization of the interaction between platelet factor 4 and homogeneous synthetic low molecular weight heparins.
    Nguyen TH; Xu Y; Brandt S; Mandelkow M; Raschke R; Strobel U; Delcea M; Zhou W; Liu J; Greinacher A
    J Thromb Haemost; 2020 Feb; 18(2):390-398. PubMed ID: 31573759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4.
    Kreimann M; Brandt S; Krauel K; Block S; Helm CA; Weitschies W; Greinacher A; Delcea M
    Blood; 2014 Oct; 124(15):2442-9. PubMed ID: 25150299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds.
    Nguyen TH; Greinacher A; Delcea M
    Nanoscale; 2015 Jun; 7(22):10130-9. PubMed ID: 25981976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia.
    Huynh A; Arnold DM; Kelton JG; Smith JW; Horsewood P; Clare R; Guarné A; Nazy I
    J Thromb Haemost; 2019 Feb; 17(2):389-399. PubMed ID: 30582672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses.
    Haile LA; Rao R; Polumuri SK; Arepally GM; Keire DA; Verthelyi D; Sommers CD
    Thromb Res; 2017 Nov; 159():39-47. PubMed ID: 28968537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential.
    Bertini S; Fareed J; Madaschi L; Risi G; Torri G; Naggi A
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):725-734. PubMed ID: 28118750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.
    Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of New Monoclonal PF4-Specific Antibodies as Useful Tools for Studies on Typical and Autoimmune Heparin-Induced Thrombocytopenia.
    Vayne C; Nguyen TH; Rollin J; Charuel N; Poupon A; Pouplard C; Normann N; Gruel Y; Greinacher A
    Thromb Haemost; 2021 Mar; 121(3):322-331. PubMed ID: 33086397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights into the binding of PF4 to long heparin oligosaccharides in ultralarge complexes using mass spectrometry.
    Shi D; Zhao H; Bu C; Fraser K; Wang H; Dordick JS; Linhardt RJ; Zhang F; Shi F; Chi L
    J Thromb Haemost; 2023 Dec; 21(12):3608-3618. PubMed ID: 37648114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of complexes of PF4 and heparins by size-exclusion chromatography coupled with multi-angle light scattering detector.
    Zhao J; Xue Y; Tian H; Qiu P; Ouyang Y; Liu H; Yi L; Zhang Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Feb; 1233():124004. PubMed ID: 38199058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid.
    Newman PM; Swanson RL; Chong BH
    Thromb Haemost; 1998 Aug; 80(2):292-7. PubMed ID: 9716155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases.
    Amiral J; Bridey F; Wolf M; Boyer-Neumann C; Fressinaud E; Vissac AM; Peynaud-Debayle E; Dreyfus M; Meyer D
    Thromb Haemost; 1995 Jan; 73(1):21-8. PubMed ID: 7740492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes.
    Krauel K; Fürll B; Warkentin TE; Weitschies W; Kohlmann T; Sheppard JI; Greinacher A
    J Thromb Haemost; 2008 Dec; 6(12):2160-7. PubMed ID: 18983520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.
    Warkentin TE; Cook RJ; Marder VJ; Sheppard JA; Moore JC; Eriksson BI; Greinacher A; Kelton JG
    Blood; 2005 Dec; 106(12):3791-6. PubMed ID: 16109780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of two synthetic oligosaccharides on platelet activation induced by plasma from HIT patients.
    Savi P; Pflieger AM; Hérault JP; Michaux C; Duchaussoy P; Petitou M; Herbert JM
    J Thromb Haemost; 2003 Sep; 1(9):2008-13. PubMed ID: 12941044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Binding Characteristics of Pathogenic Anti-Platelet Factor-4/Polyanion Antibodies to Antigens Coated on Different Substrates: A Perspective on Clinical Application.
    Nguyen TH; Greinacher A
    ACS Nano; 2018 Dec; 12(12):12030-12041. PubMed ID: 30540167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.
    Litvinov RI; Yarovoi SV; Rauova L; Barsegov V; Sachais BS; Rux AH; Hinds JL; Arepally GM; Cines DB; Weisel JW
    J Biol Chem; 2013 Nov; 288(46):33060-70. PubMed ID: 24097975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivity of platelet-activating and nonplatelet-activating anti-PF4/heparin antibodies in enzyme immunosorbent assays under different conditions.
    Nguyen TH; Wesche J; Raschke R; Strobel U; Bui VC; Delcea M; Greinacher A
    J Thromb Haemost; 2019 Jul; 17(7):1113-1119. PubMed ID: 31009154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.
    Krauel K; Hackbarth C; Fürll B; Greinacher A
    Blood; 2012 Feb; 119(5):1248-55. PubMed ID: 22049520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.
    Kizlik-Masson C; Vayne C; McKenzie SE; Poupon A; Zhou Y; Champier G; Pouplard C; Gruel Y; Rollin J
    J Thromb Haemost; 2017 Oct; 15(10):2065-2075. PubMed ID: 28771917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.